These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 23523468)
21. Cardiolipin function in the yeast S. cerevisiae and the lessons learned for Barth syndrome. Ji J; Greenberg ML J Inherit Metab Dis; 2022 Jan; 45(1):60-71. PubMed ID: 34626131 [TBL] [Abstract][Full Text] [Related]
22. New C-Terminal Conserved Regions of Tafazzin, a Catalyst of Cardiolipin Remodeling. Shilovsky GA; Zverkov OA; Seliverstov AV; Ashapkin VV; Putyatina TS; Rubanov LI; Lyubetsky VA Oxid Med Cell Longev; 2019; 2019():2901057. PubMed ID: 31781330 [TBL] [Abstract][Full Text] [Related]
26. Cardiolipin-deficient cells have decreased levels of the iron-sulfur biogenesis protein frataxin. Li Y; Lou W; Grevel A; Böttinger L; Liang Z; Ji J; Patil VA; Liu J; Ye C; Hüttemann M; Becker T; Greenberg ML J Biol Chem; 2020 Aug; 295(33):11928-11937. PubMed ID: 32636300 [TBL] [Abstract][Full Text] [Related]
28. SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome. Russo S; De Rasmo D; Rossi R; Signorile A; Lobasso S Sci Rep; 2024 Jun; 14(1):13655. PubMed ID: 38871974 [TBL] [Abstract][Full Text] [Related]
29. N-oleoylethanolamide treatment of lymphoblasts deficient in Tafazzin improves cell growth and mitochondrial morphology and dynamics. Chan JZ; Fernandes MF; Steckel KE; Bradley RM; Hashemi A; Groh MR; Sciaini G; Stark KD; Duncan RE Sci Rep; 2022 Jun; 12(1):9466. PubMed ID: 35676289 [TBL] [Abstract][Full Text] [Related]
30. The Function of Tafazzin, a Mitochondrial Phospholipid-Lysophospholipid Acyltransferase. Schlame M; Xu Y J Mol Biol; 2020 Aug; 432(18):5043-5051. PubMed ID: 32234310 [TBL] [Abstract][Full Text] [Related]
31. Aberrant cardiolipin metabolism is associated with cognitive deficiency and hippocampal alteration in tafazzin knockdown mice. Cole LK; Kim JH; Amoscato AA; Tyurina YY; Bay R H; Karimi B; Siddiqui TJ; Kagan VE; Hatch GM; Kauppinen TM Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3353-3367. PubMed ID: 30055293 [TBL] [Abstract][Full Text] [Related]
32. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells. Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285 [TBL] [Abstract][Full Text] [Related]
33. Blocking phosphatidylglycerol degradation in yeast defective in cardiolipin remodeling results in a new model of the Barth syndrome cellular phenotype. Káňovičová P; Čermáková P; Kubalová D; Bábelová L; Veselá P; Valachovič M; Zahumenský J; Horváth A; Malínský J; Balážová M J Biol Chem; 2022 Jan; 298(1):101462. PubMed ID: 34864056 [TBL] [Abstract][Full Text] [Related]
34. Cardiac mitochondrial structure and function in tafazzin-knockdown mice. Kim J; Lee K; Fujioka H; Tandler B; Hoppel CL Mitochondrion; 2018 Nov; 43():53-62. PubMed ID: 30389594 [TBL] [Abstract][Full Text] [Related]
35. Deletion of the cardiolipin-specific phospholipase Cld1 rescues growth and life span defects in the tafazzin mutant: implications for Barth syndrome. Ye C; Lou W; Li Y; Chatzispyrou IA; Hüttemann M; Lee I; Houtkooper RH; Vaz FM; Chen S; Greenberg ML J Biol Chem; 2014 Feb; 289(6):3114-25. PubMed ID: 24318983 [TBL] [Abstract][Full Text] [Related]